JP2024521098A5 - - Google Patents
Info
- Publication number
- JP2024521098A5 JP2024521098A5 JP2023571758A JP2023571758A JP2024521098A5 JP 2024521098 A5 JP2024521098 A5 JP 2024521098A5 JP 2023571758 A JP2023571758 A JP 2023571758A JP 2023571758 A JP2023571758 A JP 2023571758A JP 2024521098 A5 JP2024521098 A5 JP 2024521098A5
- Authority
- JP
- Japan
- Prior art keywords
- polypeptide
- amino acid
- acid sequence
- seq
- sequence described
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163190964P | 2021-05-20 | 2021-05-20 | |
| US63/190,964 | 2021-05-20 | ||
| US202263341771P | 2022-05-13 | 2022-05-13 | |
| US63/341,771 | 2022-05-13 | ||
| PCT/US2022/030068 WO2022246084A1 (en) | 2021-05-20 | 2022-05-19 | Sars-cov-2 polypeptides |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024521098A JP2024521098A (ja) | 2024-05-28 |
| JP2024521098A5 true JP2024521098A5 (enExample) | 2025-05-28 |
Family
ID=82321637
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023571758A Pending JP2024521098A (ja) | 2021-05-20 | 2022-05-19 | ＳＡＲＳ－ＣｏＶ－２ポリペプチド |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US12653880B2 (enExample) |
| EP (1) | EP4294440A1 (enExample) |
| JP (1) | JP2024521098A (enExample) |
| KR (1) | KR20240012394A (enExample) |
| AU (1) | AU2022277697A1 (enExample) |
| BR (1) | BR112023024034A2 (enExample) |
| CA (1) | CA3212678A1 (enExample) |
| IL (1) | IL308465A (enExample) |
| MX (1) | MX2023013665A (enExample) |
| WO (1) | WO2022246084A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4547258A4 (en) * | 2022-06-28 | 2026-08-05 | Transcode Therapeutics Inc | Matrix-Directed Rig-I Agonitor Nanoparticles and Precursor Compositions and Their Uses in Cancer Therapy |
| CN115947801B (zh) * | 2022-12-29 | 2026-02-06 | 中国疾病预防控制中心病毒病预防控制所 | 一种流感病毒通用和冠状病毒联合多肽及其疫苗的应用 |
| CN116143908B (zh) * | 2023-02-10 | 2026-07-10 | 武汉华美生物工程有限公司 | 一种针对VLPs类型抗原免疫产生高效价抗血清的方法 |
| WO2025231068A1 (en) * | 2024-04-30 | 2025-11-06 | The Regents Of The University Of Michigan | Compositions and methods for enhancing systemic and mucosal immune responses |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112013032421A2 (pt) | 2011-06-29 | 2017-01-17 | Immunotope Inc | método para profilaxia ou tratamento de uma infecção pelo vírus da dengue, método para induzir uma resposta imune mediada por linfócito t citotóxico, vacina contra o vírus da dengue, método para prevenir uma doença causada pelo vírus da dengue e método para induzir uma resposta imune a pelo menos um vírus da dengue |
| WO2015130488A2 (en) | 2014-02-28 | 2015-09-03 | Immunotope, Inc. | Mhc class i associated peptides for prevention and treatment of hepatitis b virus infection |
| WO2015175361A1 (en) | 2014-05-13 | 2015-11-19 | Immunotope, Inc. | Dengue virus specific multiple hla binding t cell epitopes for the use of universal vaccine development |
| EA201991377A1 (ru) | 2017-01-03 | 2020-01-21 | Эмерджекс Ваксинс Холдинг Лимитед | Композиции универсальной вакцины против гриппа |
| SG11202002044WA (en) | 2017-09-21 | 2020-04-29 | Emergex Vaccines Holding Ltd | MHC Class I Associated Peptides for Prevention and Treatment of Zika Virus |
| JP2021509400A (ja) | 2018-01-06 | 2021-03-25 | イマージェクス ヴァクシンズ ホールディング リミテッドＥｍｅｒｇｅｘ Ｖａｃｃｉｎｅｓ Ｈｏｌｄｉｎｇ Ｌｉｍｉｔｅｄ | 複数のフラビウイルスの予防および治療を目的としたｍｈｃクラスｉ関連ペプチド |
| AU2019244435A1 (en) | 2018-03-29 | 2020-10-15 | Emergex Vaccines Holding Limited | Vaccine compositions |
| US20210283237A1 (en) | 2018-03-29 | 2021-09-16 | Emergex Vaccines Holding Limited | Vaccine compositions |
| CA3099643A1 (en) | 2018-05-18 | 2019-11-21 | Emergex Vaccines Holding Limited | Reverse peptide vaccine |
| CR20220552A (es) | 2020-04-02 | 2023-01-17 | Regeneron Pharma | Anticuerpos contra glicoproteína de espícula anti-sars-cov-2 y fragmentos de unión al antígeno |
| WO2021204179A1 (en) * | 2020-04-09 | 2021-10-14 | Suzhou Abogen Biosciences Co., Ltd. | Nucleic acid vaccines for coronavirus |
| EP4138876A1 (en) * | 2020-04-23 | 2023-03-01 | ISA Pharmaceuticals B.V. | Immunization against sars-cov-related diseases |
| GB202008250D0 (en) | 2020-06-02 | 2020-07-15 | Emergex Vaccines Holding Ltd | Diagnosis, prevention and treatment of coronavirus infection |
| GB202011652D0 (en) * | 2020-07-28 | 2020-09-09 | Univ Oxford Innovation Ltd | Polypeptide panels and uses thereof |
| US11191827B1 (en) * | 2020-12-09 | 2021-12-07 | Tevogen Bio Inc. | COVID-19 peptide specific T-cells and methods of treating and preventing COVID-19 |
| EP4294435A1 (en) | 2021-02-16 | 2023-12-27 | Emergex Vaccines Holding Limited | Reverse peptides from coronavirus for immunogenic purposes |
| US20240269264A1 (en) | 2021-06-02 | 2024-08-15 | Emergex Vaccines Holding Limited | Human coronavirus 229e derived peptides |
-
2022
- 2022-05-19 BR BR112023024034A patent/BR112023024034A2/pt unknown
- 2022-05-19 WO PCT/US2022/030068 patent/WO2022246084A1/en not_active Ceased
- 2022-05-19 IL IL308465A patent/IL308465A/en unknown
- 2022-05-19 EP EP22735677.1A patent/EP4294440A1/en active Pending
- 2022-05-19 JP JP2023571758A patent/JP2024521098A/ja active Pending
- 2022-05-19 MX MX2023013665A patent/MX2023013665A/es unknown
- 2022-05-19 KR KR1020237039921A patent/KR20240012394A/ko active Pending
- 2022-05-19 AU AU2022277697A patent/AU2022277697A1/en not_active Abandoned
- 2022-05-19 US US17/748,715 patent/US12653880B2/en active Active
- 2022-05-19 CA CA3212678A patent/CA3212678A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN115297892A (zh) | 抗新型冠状病毒感染的mRNA疫苗的组合物和方法 | |
| US20240370011A1 (en) | Compositions and methods of ribonucleic acid respiratory syncytial virus (rsv) vaccines | |
| CN111108192A (zh) | 非人类人猿腺病毒核酸序列和氨基酸序列、含有其的载体及其用途 | |
| JP2020530765A5 (enExample) | ||
| WO2022135563A1 (zh) | 同时诱导抗多种病毒的免疫应答的方法 | |
| JP2026082958A (ja) | ゴリラ・アデノウイルスの核酸配列およびアミノ酸配列、それを含むベクター、およびそれらの使用 | |
| WO2022010813A2 (en) | Enhancing immune responses through targeted antigen expression | |
| JP2024523329A5 (enExample) | ||
| JP7642608B2 (ja) | ハンタウイルス抗原性組成物 | |
| JP4797149B2 (ja) | インフルエンザウイルスに対するベクターワクチン | |
| JP2023529124A (ja) | コロナウイルスワクチンコンストラクトおよびこれを作製し使用する方法 | |
| JP7314441B2 (ja) | 選択的ｃｄ８陽性ｔ細胞誘導ワクチン抗原 | |
| WO2022171182A1 (zh) | 一种治疗或者预防冠状病毒病突变株的疫苗试剂 | |
| US12622958B2 (en) | Virus-like particles containing RSV antigen protein and vaccines using the same | |
| JP2002510496A (ja) | 細胞傷害性ｔ細胞を誘導するための医薬 | |
| WO2025075129A1 (ja) | コロナウイルススパイクタンパク質変異体 | |
| US9060973B2 (en) | Vaccine for enveloped viruses | |
| WO2025260633A1 (zh) | Rsv和hmpv融合f蛋白及其用途 | |
| EP2530162A1 (en) | Biomolecule surface display and uses thereof | |
| WO2022195900A1 (ja) | 組換え麻疹ウイルス | |
| CN116457011A (zh) | 用于治疗冠状病毒的疫苗组合物 | |
| JP2024525578A5 (enExample) | ||
| MX2007006423A (en) | Protein delivery system |